01:29 AM EDT, 10/12/2026 (MT Newswires) -- Hofseth BioCare (HBC.OL) said that the Financial Supervisory Authority of Norway, or Finanstilsynet, approved the listing prospectus for the second tranche of its private placement. The 32,819,999 shares under the second tranche were initially delivered on a non-tradable ISIN pending the approval and publication of the listing prospectus, the Norwegian specialty ingredients company said in an Oct. 9 filing. The private placement comprised a total of 111,154,608 shares at 1.30 Norwegian kroner apiece, generating gross proceeds of 144.5 million kroner for the company.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.